Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.

Gynecologic oncology - 1 Aug 2023

Jamieson Amy, McConechy Melissa K, Lum Amy, Leung Samuel, Thompson Emily F, Senz Janine, Talhouk Aline, Huntsman David G, Bashashati Ali, Gilks C Blake, McAlpine Jessica N

Abstract excerpt

OBJECTIVES: Despite recommendations for integrating molecular classification of endometrial cancers (EC) into pathology reporting and clinical management, uptake is inconsistent. To assign ProMisE subtype, all molecular components must be available (POLE mutation status, mismatch repair (MMR) and p53 immunohistochemistry (IHC)) and often these are assessed at different stages of care and/or at different centres...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mismatch Repair
Share to Endometrial and Cervical Cancer Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Microsatellite Instability

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37321155
DOI: 10.1016/j.ygyno.2023.05.073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Harmonized molecular classification; assessment of a single-test ProMisE NGS tool.PMID 37321155Read ↗

Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.Semantic proximity Read ↗

Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier.Semantic proximity Read ↗

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Semantic proximity Read ↗

Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma.Semantic proximity Read ↗

Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes.Semantic proximity Read ↗

Implementation of the ProMisE classifier and validation of its prognostic impact in Brazilian endometrial carcinomasSemantic proximity Read ↗

Preoperative molecular classification of endometrial cancer: Validation through biopsy and matched hysterectomy specimens.Semantic proximity Read ↗

Advantages of next-generation sequencing (NGS) in the molecular classifi cation of endometrial carcinomas - our experience with 270 cases.Semantic proximity Read ↗

Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.Semantic proximity Read ↗

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.Semantic proximity Read ↗

Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.Semantic proximity Read ↗

Initiation of molecular testing of endometrial carcinomas in a population‐based setting: practical considerations and pitfallsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.